NCT06048692

Cefepime and Unictam on Preventing Post-Cesarean Surgical Site Infections

The Impact of Cefepime and Unictam on Preventing Post-Cesarean Surgical Site Infections

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 213 (actual)
• Sponsor: Beni-Suef University · Academic / Other
• Sex: Female
• Age: 18 Years – 40 Years
• Healthy volunteers: Not accepted

Summary

the aim of this study is to evaluate the efficacy of employing cefepime (CFM) versus ampicillin/sulbactam (AMS) in lowering the rate of post-cesarean surgical site infections.

Detailed description

A prospective randomized clinical study conducted in the department of obstetrics and gynecology of Beni-Suef University Hospital . A total of 213 women were assessed for eligibility, 13 of which were excluded. A total of 200 pregnant women who were eligible for elective cesarean sections (CS). The overall median duration of postoperative followed up was from 10 days to one month to determine the surgical site infection (SSI).

Conditions

• Cesarean Section; Infection

Interventions

Type	Name	Description
DRUG	Cefepime 1000 MG	Cefepime is a fourth-generation cephalosporin antibiotic
DRUG	Ampicillin-sulbactam	Broad-Spectrum Antibiotic

Timeline

• Start date: 2023-01-01
• Primary completion: 2023-09-15
• Completion: 2023-09-20
• First posted: 2023-09-21
• Last updated: 2023-09-21

Locations

1 site across 1 country: Egypt